Formulation and Evaluation of Sustained Release Matrix Tablets of Glipizide Sustained release matrix tablets of glipizide
Iranian Journal of Pharmaceutical Sciences,
Vol. 5 Núm. 4 (2009),
1 تشرين الأول 2009
,
Página 205-214
https://doi.org/10.22037/ijps.v5.41224
Resumen
The purpose of this study was to develop a new monolithic matrix tablet to completely deliver glipizide in a zero order manner over a sustained period. Two approaches were examined using drug in a formulation that contain polymer like hydroxylpropyl methyl-cellulose K 100 (HPMCK) and Eudragit L100. The granules were prepared by wet granulation method and thereby formulated as F-1, F-2. F-3 and F-4 by using the above bring up polymers with other ingredients. The granules of different formulations were evaluated for angle of repose, loose bulk density and tapped density, compressibility index, total porosity,and drug content. The angle of repose and compressibility index (%) ranged from 25.0±0.8to 28.0±1.1 and 12.92±0.02 to 13.08±0.03, respectively. The results of angle of repose (<30)indicate good flow properties of the granules. This was further supported by lower com-pressibility index values. The granules showed satisfactory flow properties, compressibility and drug content. All of the formulations showed uniform thickness (C.V< 0.5%), uniform weight with little significance difference were observed with varying formulation composition.In the weight variation test, the pharmacopoeial limit for the percentage of deviation for tablets of more than 130 mg to 324 mg is 7.5 % difference. Technological characterizations (thickness, diameter, weight variation test, drug content, hardness, and friability) were conceded with the formulated matrix tablet and in vitrodrug release was measured by meansof dissolution apparatus. Of the various formulation distinguished, out of which, theformulation (F3) were preferred to be full of 30 mg of HPMCK and 35 mg of Eudragit L100was subjected to stability were accomplished studies for three months at 4 °C. The roomtemperature (25 °C) and (45 °C) with relative humidity 75±5% were maintained and itsstability with respect to release pattern. The kinetic release treatment showed that therelease of drug follows zero order kinetic (r2= 0. 9959), Koresmeyer equation gave valueof r2= 0.9853 which was close to one indicating that the drug was released by zero orderkinetic. According to Koresmeyer equation, the formulation F-1, F-2, and F-4 showed the regression values of 0.9823, 0.9785, and 0.9742, respectively. The identical plot for (logcumulative percentage drug release vs time) for Koresmeyer-Peppas equation indicated agood linearity for the commercially available sustained release tablet and formulation F-3 with regression values of 0.9619 and 0.9959, respectively. Scanning electron microscope confirmed both diffusion and erosion mechanism for the optimized batch of matrix tabletF-3. Results suggest that the formulated tablet F-3 of glipizide could perform therapeuti-cally better than the reachable marketed drug leading to improve better efficacy.
- Eudragit L100
- Glipizide
- HPMC K 100
- Matrix tablet
- Sustained release
Cómo citar
Citas
[2]Chein YW. Novel drug delivery systems. 2nd ed.New York: Marcel Dekker Inc., 1997; pp.1-42.
[3]Ritchel WA. Biopharmaceutic and pharmacoki-netic apects in the design of controlled release per-oral drug deliver system. Drug Dev Ind Pharm1989; 15: 1073-103.
[4]Reddy KR, Mutalik S, Reddy S. Once daily sustained release matrix tablets of nicorandinal formulation in vitroevaluation. AAPS Pharm Sci Tech2003; 4: 1-9.
[5]Mohammed AD, James LF, Michael HR, John EH, Rajabi-Siahboomi AR. Release of propranolol hydrochloride from matrix tablets containing sodium carboxymethylcellulose and hydrox-ypropylmethylcellulose.Pharm Dev Tech 1999;4: 313-24.
[6]Verma RK, Garg S. Development and evaluation of osmotically controlled oral drug delivery system of glipizide. Eur J Pharm Biopharm 2004; 57: 513-25.
[7]Jamzad S, Fassihi R. Development of controlled release low dose class II drug-glipizide. Int J Pharm2006; 312: 24-32.
[8]Rodriguez L, Caputo O, Cini M, Cavallari C,Grecchi R. In vitrorelease of theophylline from directly-compressed matrices containing methacrylic acid copolymers and/or dicalcium phosphate dihydrate.Ill Farmaco1993; 48: 1597-604.
[9]Sweetman SC. Martindale, the complete drug reference. 34thed. London: Pharmaceutical Press, 2005; pp. 324-48.
[10]Patel JK, Patel RP, Amin AF, Patel MM.Formulation and evaluation of glipizide microspheres. AAPS Pharm Sci Tech2005; 6:49-55.
[11]Chowdary KPR, Rao YS. Design and in vitro and in vivoevaluation of mucoadesive microcapsules of glipizide for oral controlled release. AAPS Pharm Sci Tech2003; 4: 1-6.
[12]Cooper J, Gunn C. Powder flow and compaction.In: Carter SJ, (editor). Tutorial pharmacy. New Delhi: CBS Publishers and distributors, 1986;pp. 211-33.
[13]Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. Philadelphia:Lea & Febieger, 1970; pp. 68-9.
[14]The Pharmacopoeia of India. New Delhi:Controller of Publication, 1996; pp.736.
[15]Rawlins EA. Bentley's text book of pharmaceutics.London: Cassell and Colloer Macmillian, 1977.
[16]Hadjioannou TP, Christain GD, Koupparis MA.Quantitative calculations in pharmaceutical practice and research. New York: VCH Publishers Inc., 1993; pp. 345-8.
[17]Bourne DW. Pharmacokinetics. In: Banker GS,Rhoides CT, (editors). Modern pharmaceutics. 4th ed. New York: Marcel Dekker Inc. 2002; 67-92.
[18]Aulton ME, Wells TL. Pharmaceutics, the science of dosage form design. London: Churchill,Livingstone, 1988.
[19]Martin A. Physical pharmacy. Baltimore:Lippincott Williams and Wilkins, 2001; p. 423.
[20]Lachman L, Lieberman HA, Kanig JL. The theory & practice of industrial pharmacy. Mumbai:Varghese Publishing House, 1987; p. 293.
[21]Sanchez-Lafuente C, Faucci MT, Fernandez-Arevels M, Alvarez FJ, Rabasco AM, Mura P.Development of sustained release matrix tablets of didanosine contain is methacyclic and ethyl cellulose polymers. Int J Pharm 2002; 234: 213-21.
[22]Saravanan M, Natraj KS, Ganesh KS.Hydroxypropyl methyl cellulose based cephalexin extended release tablets: Influence of tablet formulation, hardness and storage on in vivo release kinetics. Chem Pharm Bull2003; 51:978-83.
[23]Defang O, Shufang NL.In vitroand in vivo evaluation of two extended release preparation sof combination metformin and glipizide. Drug Dev Ind Pharm2005; 31: 677-85.
[24]Saravanan M, Natraj KS, Ganesh KS. The effect of tablet formulation and hardness on in vitro release of cephalexin from Eudragit L100 based extended release tablets. Biol Pharm Bull2002;25: 4541-5.[25]Reddy KR, Mutalik S, Reddy S. Once daily sustained release matrix tablets of nicorandrail,formulation and in vitroevaluation. AAPS Pharm Sci Tech2003; 4: 61.
[26]Fassihi RA, Ritschel WA. Multiple layer, direct compression controlled release system, in vitro and in vivoevaluation. J Pharm Sci 1993; 82: 750-4.
[27]Basak SC, Jayakumar Reddy BM, Lucas Mani KP. Formulation and release behavior of sustained release Ambroxol hydrochloride HPMC matrix tablet. Indian Pharm Sci2006; 5: 594-7.
- Resumen ##plugins.themes.ojsPlusA.frontend.article.viewed##: 88 ##plugins.themes.ojsPlusA.frontend.article.times##
- IJPS_Volume 5_Issue 4_Pages 205-214 (English) ##plugins.themes.ojsPlusA.frontend.article.downloaded##: 34 ##plugins.themes.ojsPlusA.frontend.article.times##